Myocarditis related SARS-CoV-2 infection or vaccination: an expert consensus statement on its diagnosis and management

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has revealed several cardiovascular complications, including myocarditis caused by SARS-CoV-2 infection (COVID-19) or after messenger RNA vaccine administration. Because of the high prevalence of COVID-19, the expansion of vaccination programs, and the appearance of new information on myocarditis in these contexts, there is a need to condense the knowledge acquired since the start of the pandemic. To meet this need, this document was drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology, with the collaboration of the Spanish Agency for Medicines and Health Products (AEMPS). The document aims to address the diagnosis and treatment of cases of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration. ⠂C 2023 Sociedad Espan & SIM;ola de Cardiologia. Published by Elsevier Espan & SIM;a, S.L.U. All rights reserved.

Automated summary

This document, drafted by the Myocarditis Working Group of the Heart Failure Association of the Spanish Society of Cardiology in collaboration with the Spanish Agency for Medicines and Health Products (AEMPS), aims to summarize the knowledge acquired since the start of the SARS-CoV-2 pandemic regarding the diagnosis and treatment of myocarditis associated with SARS-CoV-2 infection or messenger RNA vaccine administration.